Literature DB >> 15356571

IL-4-independent pathways exacerbate methacholine-induced airway hyperreactivity during mycoplasma respiratory disease.

Matthew D Woolard1, R Doug Hardy, Jerry W Simecka.   

Abstract

BACKGROUND: Mycoplasma respiratory infections are associated with wheezing and exacerbation of airway hyperresponsiveness (AHR) in asthmatic patients. IL-4 is a key cytokine in the development of AHR and airway reconstruction in asthmatic patients and might be an important component in exacerbation of AHR during pulmonary mycoplasma infection.
OBJECTIVE: This study evaluates the effect of IL-4 on the severity of methacholine-induced AHR associated with mycoplasma pulmonary mycoplasma infection.
METHODS: BALB/c and IL-4 knockout (KO) mice were infected with Mycoplasma pulmonis, and their enhanced pause scores were monitored before and after methacholine inhalation with whole-body plethysmography.
RESULTS: IL-4 KO mice showed no difference in histopathology of the lungs before or after Mycoplasma pulmonis infection when compared with BALB/c mice. There was an increase in airway obstruction from days 7 to 21 after infection in both strains of mice, but there was no strain difference in airway resistance-associated mycoplasma disease. However, IL-4 KO mice had significantly higher methacholine-induced AHR after M pulmonis infection when compared with BALB/c mice. There was no difference in AHR between uninfected IL-4 KO and control mice.
CONCLUSION: In contrast to our hypothesis, IL-4-independent pathways exacerbate methacholine-induced AHR and promote airway obstruction during the pathogenesis of mycoplasma respiratory disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356571     DOI: 10.1016/j.jaci.2004.06.019

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

1.  Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among mycoplasma pneumoniae strains.

Authors:  Chonnamet Techasaensiri; Claudia Tagliabue; Marianna Cagle; Pooya Iranpour; Kathy Katz; Thirumalai R Kannan; Jacqueline J Coalson; Joel B Baseman; R Doug Hardy
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

2.  THE MULTIFACETED ROLE OF T CELL-MEDIATED IMMUNITY IN PATHOGENESIS AND RESISTANCE TO MYCOPLASMA RESPIRATORY DISEASE.

Authors:  Nicole A Dobbs; Adam N Odeh; Xiangle Sun; Jerry W Simecka
Journal:  Curr Trends Immunol       Date:  2009

3.  Cytokine and chemokine transcription profile during Mycoplasma pulmonis infection in susceptible and resistant strains of mice: macrophage inflammatory protein 1beta (CCL4) and monocyte chemoattractant protein 2 (CCL8) and accumulation of CCR5+ Th cells.

Authors:  Xiangle Sun; Harlan P Jones; Lisa M Hodge; Jerry W Simecka
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

4.  Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmonary inflammation.

Authors:  C M Salvatore; M Fonseca-Aten; K Katz-Gaynor; A M Gomez; A Mejias; C Somers; S Chavez-Bueno; G H McCracken; R D Hardy
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

5.  Intranasal interleukin-12 therapy inhibits Mycoplasma pneumoniae clearance and sustains airway obstruction in murine pneumonia.

Authors:  C M Salvatore; M Fonseca-Aten; K Katz-Gaynor; A M Gomez; R D Hardy
Journal:  Infect Immun       Date:  2007-11-26       Impact factor: 3.441

6.  Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin.

Authors:  R Doug Hardy; Jacqueline J Coalson; Jay Peters; Adriana Chaparro; Chonnamet Techasaensiri; Angelene M Cantwell; T R Kannan; Joel B Baseman; Peter H Dube
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

7.  Dietary acacetin reduces airway hyperresponsiveness and eosinophil infiltration by modulating eotaxin-1 and th2 cytokines in a mouse model of asthma.

Authors:  Wen-Chung Huang; Chian-Jiun Liou
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-24       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.